×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Femasys secures nearly $7M in funding from PharmaCyte
MassDevice
Femasys this week announced it received a strategic upfront investment of $6.85 million from biotech company PharmaCyte Biotech.
6 months ago
PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business
Simply Wall Street
Since it has a market capitalisation of US$20m, PharmaCyte Biotech's US$2.1m in cash burn equates to about 10% of its market value. As a result,...
2 months ago
MyMD Pharmaceuticals Secures Strategic Investments
citybiz
BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage biopharmaceutical company committed to developing...
13 hours ago
PharmaCyte Biotech Announces Final Results of Tender Offer
Yahoo Finance
LAS VEGAS, June 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") today announces the final results of its...
11 months ago
PharmaCyte forced to think outside the box as CEO departs amid ongoing clinical hold
Fierce Biotech
PharmaCyte forced to think outside the box as CEO departs amid ongoing clinical hold ... Long-time PharmaCyte CEO Kenneth Waggoner has departed...
19 months ago
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
Business Wire
Waggoner, commented, “We are pleased to have reached this constructive agreement with Iroquois which we believe is in the best interest of all...
21 months ago
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
Yahoo Finance
LAS VEGAS, May 11, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") today announces a cash tender offer for up...
12 months ago
PMCB: After Nasdaq Uplisting, PharmaCyte Biotech Looks Ready to Rumble
StockNews.com
In July, PharmaCyte Biotech announced that it would effect a 1-for-1,500 reverse share split of its common stock. These shares would commence...
32 months ago
Cell-in-a-Box: PharmaCyte seeks FDA advice for inoperable cancer trial
biopharma-reporter.com
Living Capsules. PharmaCyte manufactures these cell-in-a-box therapies under cGMP standards with its supplier, Austrianova, at a facility in...
88 months ago
PharmaCyte live-cell encapsulation tech heads to Ph II trials targeting pancreatic cancer
outsourcing-pharma.com
PharmaCyte's live-cell encapsulation technology could change the way solid tumor cancers are treated, says CEO, as the biotech moves forward...
73 months ago